Phase III trial comparing granylocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: Results of the BCIRG 004 trial

Clinical Breast Cancer

Volumn 3, Issue 4, 2002, Pages 268-275

  Nabholtz, Jean Marc ^a,b   Cantin, Jacques ^c   Chang, Jose ^d   Guevin, Raymond ^c   Patel, Ravi ^e   Tkaczuk, Katherine ^f   Vodvarka, Pavel ^h   Reese, David ^b   Riva, Alessandro ^b   Mackey, John ^g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Cancer International Research Group   (United States)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d LAKERIDGE HEALTH CORPORATION   (Canada)

^e CHUM Pavillon Saint Luc ^*  (United States)

^f UNIVERSITY OF MARYLAND   (United States)

^g CROSS CANCER INSTITUTE   (Canada)

^h Cross Cancer Institute ^*

Author keywords

Febrile neutropenia; Filgrastim; Interleukin 3 receptor; Myelopoietin; Prophylaxis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GROWTH FACTOR; INTERLEUKIN 3 RECEPTOR; LERIDISTIM; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; BREAST METASTASIS; CLINICAL TRIAL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEBRILE NEUTROPENIA; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; SKIN DISEASE; STOMATITIS;

EID: 0036814402     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2002.n.030     Document Type: Article

References (24)

1. Group EBCTC. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352:332-342.
2. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16:3439-3460.
3. Chevallier B, Fumoleau P, Kerbrat P, at al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13:314-322.
4. van Oosterom AT, Schrijvers D, Schriivers D. Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. Anticancer Drugs 1995; 6:356-368.
5. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol 1999; 17:2341-2354.
6. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 1999; 17:1413-1424.
7. Misset JL, Dieras V, Gruia G, et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999; 10:553-560.
8. Sparano JA, O'Neill A, Schaefer PL, et al. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol 2000; 18:2369-2377.
9. Nabholtz JM, Mackey JR, Smylie M, et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 2001; 19:314-321.
10. Nabholtz J, Falkson G, Campos D, et al. A phase III trial comparing doxorubicin and docetaxel (AT) to doxorubicin and cyclophosphamide (AC) as first line therapy for MBC. Proc Am Soc Clin Oncol 1999; 18:127a (Abstract #485).
11. Nabholtz J, Paterson A, Dirix L, et al. A phase III randomized trial comparing docetaxel (T), doxorubicin (A), and cyclophosphamide (C) (TAC) to FAC as first-line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2001; 20:22a (Abstract #83).
12. Ozer H, Armitage J, Bennett C, et al. 2000 update of recommendations for the use of hemotopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel 2001; 19:1583-1585.
13. Johnston EM, Crawford J. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Semin Oncol 1998; 25:552-561.
14. Monahan J, Welphy J, Hood W, et al. Myelopoietin: biochemical mechanism of action studies. Blood 1998; 92:174b (Abstract #3733).
15. Monahan JB, Hood WF, Welply JK, et al. Bivalent binding and signaling characteristics of leridistim, a novel chimeric dual agonist of interleukin-3 and granulocyte colony-stimulating factor receptors. Exp Hematol 2001; 29:416-424.
16. MacVittie TJ, Farese AM, Smith WG, et al. Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppression. Blood 2000; 95:837-845.
17. MacVittie TJ, Farese AM, Davis TA, et al. Myelopoietin, a chimeric agonist of human interleukin 3 and granulocyte colony-stimulating factor receptors, mobilizes CD34+ cells that rapidly engraft lethally x-irradiated non-human primates. Exp Hematol 1999; 27:1557-1568,
18. Abboud C, DiPersio J, Gordon L, et al. Phase I/II study to determine the safety and tolerability of SC-70935 in patients with relapsed lymphoma receiving ESHAP Blood 1997; 90(suppl 1):173a (Abstract #765).
19. Hamm J, Merkel D, Mortimer J, et al. A phase I/II study of SC-70935, a novel hematopoietic growth factor with dual receptor against activity, demonstrates enhanced neutrophil recovery in advanced breast cancer patients receiving docetaxel. Proc Am Soc Clin Oncol 1998; 17:6a (Abstract #296).
20. Koch GG, McCanless I, Ward JF, Jr. Interpretation of statistical methodology associated with maintenance trials. Am J Med 1984; 77:43-50.
21. Zhang J, Boos DD. Mantel-Haenszel test statistics for correlated binary data. Biometrics 1997; 53:1185-1198.
22. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325:164-170.
23. Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328-340.
24. Dempke W, Von Poblozki A, Grothey A, et al. Human hematopoietic growth factors: old lessons and new perspectives. Anticancer Res 2000; 20:5155-5164.